Skin Cancer News and Research

Latest Skin Cancer News and Research

New drug better than chemotherapy for skin cancer patients

A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study (“BREAK-3” trial) published Online First in the Lancet.

26 Jun 2012

Skin patch treatment kills common skin cancer

A skin patch treatment for basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.

25 Jun 2012

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

Skin patch treatment kills common skin cancer

A skin patch treatment for a common type of skin cancer called basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.

22 Jun 2012

Smoking increases skin cancer risk

Individuals who smoke may be increasing their risk for developing a type of skin cancer called squamous cell carcinoma, a review of published studies suggests.

22 Jun 2012

Patients with MS appear to have reduced risk of cancer

Multiple sclerosis (MS) patients appear to have a lower cancer risk, according to a new study led by researchers at the University of British Columbia and Vancouver Coastal Health.

22 Jun 2012

Sun exposure, vitamin D and pancreatic cancer risk

High levels of ultraviolet radiation at an individual's birth location, sun-sensitive skin type and a history of skin cancer each decreased risk for pancreatic cancer, according to study results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Zebrafish provides insight into human melanoma

A transparent member of the minnow family is providing researchers at Weill Cornell Medical College in New York City with insight into human melanoma - a form of skin cancer - that may lead to new or repurposed drug treatments, for skin and other cancers.

19 Jun 2012

Drug shows promise as skin cancer treatment

A new drug for a type of skin cancer caused by a rare genetic disease can not only substantially shrink the tumors, but can also prevent the growth of new cancers, US investigators have discovered.

15 Jun 2012

Skin cancer does not discriminate between skin colors

Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.

15 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.

14 Jun 2012

Vitamin A supplements may reduce skin cancer risk

Taking vitamin A supplements reduces the risk for developing a deadly form of skin cancer called melanoma, say US researchers.

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

6 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.

4 Jun 2012

Two pharma companies plan international trials into targeted cancer treatments in the UK

A Cancer Research UK initiative to improve cancer gene testing has prompted two pharmaceutical companies to plan pioneering international trials into targeted cancer treatments in the UK.

2 Jun 2012

Imiquimod and PDT equivalent for superficial basal cell carcinoma

Imiquimod cream and photodynamic therapy for superficial basal cell carcinoma result in near equivalent rates of tumor-free survival after 1 year of treatment, a review shows.

1 Jun 2012